Bioequivalence and Bioavailability Forum 00:41 CET

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

PK Stat analysis for Levothyroxine sodium studies for USFDA submission [Design Issues]

posted by Pandu - India, 2017-10-23 06:23  - Posting: # 17904
Views: 1,709

Hi,
We are conducting Levothyroxine sodium studies for USFDA submission, I required one clarity as per OGD.

OGD says that Post-dose levothyroxine measurements by the baseline levothyroxine value should be corrected in each period for each subject. The baseline value should be obtained from the average of three levothyroxine measurements taken before dosing (i.e., at 0.5 h, 0.25 h, and 0 h pre-dose.

OGD is not mentioned about exclusion of subjects from Pharmacokinetic and statistical analysis, after baseline correction if subject having more-than 5% of Cmax on pre-dose concentration. This criteria we can apply for endogenous products or not?

Awaiting for your replays.

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,931 posts in 4,039 threads, 1,285 registered users;
online 7 (0 registered, 7 guests [including 5 identified bots]).

A drug is not bad. A drug is a chemical compound.
The problem comes in when people who take drugs treat them
like a license to behave like an asshole.    Frank Zappa

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed